2015 American Transplant Congress
Everolimus and Early Calcineurin Inhibitor Withdrawal Is Associated With Superior Renal Function: 5-Year Follow-Up of the Randomized PROTECT Liver Transplantation Study
PROTECT Study Group, Novartis Pharma GmbH, Germany.
Purpose: At the end of the 12-month (M) PROTECT core study (NCT00378014), de novo liver transplant recipients (LTxR) who switched from a calcineurin inhibitor (CNI)…2015 American Transplant Congress
Proximal Tubular Dysfunction Is Common After the First Year of Kidney Transplantation
Background: After the initial period of kidney transplantation, the prevalence of proximal tubular dysfunction (PTD) and its consequences are unknown. The aim of this study…2015 American Transplant Congress
Improved Renal Function Post-Liver Transplant With Earlier Everolimus Conversion
Calcineurin inhibitors (CNI) play an important role in preventing acute rejection (AR) post-liver transplant. Its long-term use is limited by development of nephrotoxicity. Optimal timing…2015 American Transplant Congress
The Effect of Compatibility of ABO Blood Type Antigens on Graft Survival of Intestinal Transplants
Due to the introduction of new immunosuppressive agents and development of pre- and post-transplant patient management, ABO blood group incompatibility is no longer considered an…2015 American Transplant Congress
Impacts of Mycophenolate Mofetile Addition to Very Low Exposure Everolimus and Calcineurine Inhibitor Based Immunosuppression in De Novo Kidney Transplantation
Purpose: Prospective randomized study of MMF addition to everolimus (EVR) based immunosuppression was evaluated in clinical outcomes as well as protocol biopsies findings and donor…2015 American Transplant Congress
Costimulation Blockade Prevents Rejection of Vascularized Composite Allografts
[Background] Vascularized composite allotransplantation (VCA) is an emerging new era in transplant medicine and has become a valid therapeutic option after devastating tissue loss. The…2015 American Transplant Congress
Immunosuppression and Reoperation After Simultaneous Kidney Pancreas Transplantation Convey Greatest Risk for Rejection
Background: Episodes of acute cellular rejection (ACR) convey significant morbidity after simultaneous kidney and pancreas transplantation (SPK). The role of recipient sensitization, immunosuppression (IS) and…2015 American Transplant Congress
Characterization of Peripheral Blood T and B Cells of Sensitized Kidney Transplant Recipients With Long Term Stable Graft Function
We examined the phenotype of T and B cells of peripheral blood of sensitized kidney transplant recipients with stable graft function (GFR > 29mL/min) enrolled…2015 American Transplant Congress
Once Daily Dosing Is as Effective as Twice Daily Dosing of Immediate Release Tacrolimus
1Barnes-Jewish Hospital, St. Louis; 2Washington University School of Medicine, St. Louis.
Purpose: Extended release (ER) tacrolimus (tac) has been available as Advagraf® for many years and as Astagraf XL® in the US since 2013. Immediate release…2015 American Transplant Congress
Post Hoc Subgroup Analysis of ZEUS: Outcome on Renal Function, Efficacy and Safety in Living-Donor Kidney Transplant Recipients After Conversion from a Calcineurin Inhibitor to an Everolimus Based Regimen: 5 Year Follow-Up Data
1ZEUS Study Group, Germany; 2ZEUS Study Group, Switzerland; 3Novartis, Pharma, Germany.
Background: To study renal function and patient outcome after 5 years in living donation subgroup of kidney de novo transplant recipients after conversion to an…
- « Previous Page
- 1
- …
- 127
- 128
- 129
- 130
- 131
- …
- 138
- Next Page »